All In Biotech

Drug Trial Radar · NCT07392177

Understanding the Role of the Locus Coeruleus in Insomnia

An Alpha2-adrenoceptor Agonist to Reduce Locus Coeruleus Activity During Sleep in Adults With Insomnia Disorder: a Pilot Randomised Placebo-controlled Cross-over Study

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Aug 12, 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Woolcock Institute of Medical ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research project aims to better understand the neurobiological mechanistic underpinnings of insomnia disorder. The main question is whether cortical hyperarousal in individuals with insomnia disorder, measured by electroencephalograhic (EEG) infraslow oscillation coupling of sigma power during non-rapid eye movement (NREM) sleep and theta power during rapid eye movement (REM) sleep, is related to locus coeruleus activity.

Conditions

  • Insomnia

Interventions

  • DexmedetomidineDrug

    A buccal tablet containing 96 µg dexmedetomidine will be taken before habitual bedtime.

  • PlaceboDrug

    Placebo tablets will contain identical excipient without the active ingredient (dexmedetomidine) and manufactured under the same condition as the active. Placebo tablets, packs and instructions will be identical in every respect to enable the double-blind study design.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Electrographic (EEG) signaturesTime frame: Baseline and 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Woolcock Institute of Medical Research

    Macquarie Park, New South Wales, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.